Literature DB >> 12890189

Elevated matrix metalloproteinase-2 and -3 production from human diabetic dermal fibroblasts.

S J Wall1, M J Sampson, N Levell, G Murphy.   

Abstract

BACKGROUND: Diabetic foot ulcers are characterized by elevated levels of matrix metalloproteinases (MMP), which could lead to excessive matrix breakdown and disruption to healing. It is unknown if this elevation is a function of wound healing, or if it is present within normal skin and a primary contributor to the increased risk of impaired healing.
OBJECTIVES: To determine whether diabetic fibroblasts from unwounded skin show elevated MMP production compared with their nondiabetic counterparts. PATIENTS AND METHODS: Circular skin biopsies (4 mm diameter) were taken from the inside upper arm of four controls without diabetes and from four subjects with insulin-treated diabetes. Fibroblasts were incubated for a further 72 h and conditioned medium was collected and stored at -20 degrees C. The conditioned medium was assessed by gelatin zymography and Western blotting for MMP-2 and MMP-3.
RESULTS: Diabetic dermal fibroblasts showed significantly elevated production of MMP-2 (P < 0.05) and pro-MMP-3 (P < 0.05) when compared with their nondiabetic counterparts.
CONCLUSIONS: Dermal fibroblasts from normal unwounded skin are characterized by increased MMP production and this may be a primary contributing factor to the increased risk of nonhealing foot ulceration in diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12890189     DOI: 10.1046/j.1365-2133.2003.05262.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  25 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 3.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

4.  Biofilms and delayed healing - an in vitro evaluation of silver- and iodine-containing dressings and their effect on bacterial and human cells.

Authors:  Katie A Bourdillon; Craig P Delury; Breda M Cullen
Journal:  Int Wound J       Date:  2017-05-14       Impact factor: 3.315

Review 5.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

6.  Mesenchymal stem cells correct impaired diabetic wound healing by decreasing ECM proteolysis.

Authors:  Junwang Xu; Carlos Zgheib; Maggie M Hodges; Robert C Caskey; Junyi Hu; Kenneth W Liechty
Journal:  Physiol Genomics       Date:  2017-08-25       Impact factor: 3.107

Review 7.  Redox Signaling in Diabetic Wound Healing Regulates Extracellular Matrix Deposition.

Authors:  Britta Kunkemoeller; Themis R Kyriakides
Journal:  Antioxid Redox Signal       Date:  2017-08-10       Impact factor: 8.401

8.  Mesenchymal stem cells induce dermal fibroblast responses to injury.

Authors:  Andria N Smith; Elise Willis; Vincent T Chan; Lara A Muffley; F Frank Isik; Nicole S Gibran; Anne M Hocking
Journal:  Exp Cell Res       Date:  2009-08-08       Impact factor: 3.905

9.  Myofibroblast progenitor cells are increased in number in patients with type 1 diabetes and express less bone morphogenetic protein 6: a novel clue to adverse tissue remodelling?

Authors:  T Q Nguyen; H Chon; F A van Nieuwenhoven; B Braam; M C Verhaar; R Goldschmeding
Journal:  Diabetologia       Date:  2006-03-18       Impact factor: 10.122

10.  Absence of telomere shortening and oxidative DNA damage in the young adult offspring of women with pre-gestational type 1 diabetes.

Authors:  J A Cross; C Brennan; T Gray; R C Temple; N Dozio; J C Hughes; N J Levell; H Murphy; D Fowler; D A Hughes; M J Sampson
Journal:  Diabetologia       Date:  2008-11-26       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.